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Abstract
The dynorphin (Dyn) A analog zyklophin ([N-benzyl-Tyr1-cyclo(D-Asp5,Dap8)]dynorphin 
A(1-11)NH2) is a kappa opioid receptor (KOR) selective antagonist in vitro, is active in vivo and 
antagonizes KOR in the CNS after systemic administration. Hence, we synthesized zyklophin 
analogs to explore the structure-activity relationships of this peptide. The synthesis of selected 
analogs required modification to introduce the N-terminal amino acid due to poor solubility and/or 
to avoid epimerization of this residue. Among the N-terminal modifications the N-phenethyl and 
the N-cyclopropylmethyl substitutions resulted in the analogs with the highest KOR affinities. 
Pharmacological results for the alanine-substituted analogs indicated that Phe4 and Arg6, but 
interestingly not the Tyr1, phenol are important for zyklophin’s KOR affinity, and Arg7 was 
important for KOR antagonist activity. In the GTPγS assay while all of the cyclic analogs 
exhibited negligible KOR efficacy, the N-phenethyl-Tyr1, N-CPM-Tyr1 and the N-benzyl-Phe1 
analogs were 8- to 24-fold more potent KOR antagonists than zyklophin.
Introduction
While clinically used drugs acting at opioid receptors primarily interact with mu opioid 
receptors (MOR), extensive research has explored potential therapeutic applications of 
ligands for other opioid receptors. Kappa opioid receptor (KOR) antagonists were initially 
used only as pharmacological tools, but recently they have been explored for potential 
therapeutic use in the treatment of depression,1–4 anxiety4–6 and opiate and cocaine 
addiction.2, 4, 7, 8 The non-peptide KOR antagonists nor-binaltorphimine (norBNI) and 
JDTic [(3R)-7-hydroxy-N-[(2S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-
yl]-3-methylbutan-2-yl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide] have been used 
extensively to study KOR involvement in physiological processes and disease states,9 and 
JDTic was examined in a Phase I clinical trial.10 However, these prototypical KOR selective 
antagonists exhibit exceptionally long KOR antagonist activity, lasting weeks after a single 
*Corresponding Author: janealdrich@ufl.edu Phone: 1-352-273-8708. Fax: 352-392-9455.
†Present Address: Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA 23298.
§Department of Medicinal Chemistry, University of Florida, Gainesville, FL 32610.
Author Contributions
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the 
manuscript.
The authors declare no competing financial interest.
HHS Public Access
Author manuscript
J Med Chem. Author manuscript; available in PMC 2016 November 25.
Published in final edited form as:













dose,9 which complicate their use as pharmacological tools and could impact their 
therapeutic application.
Our research group has designed and synthesized analogs of the endogenous kappa opioid 
peptide dynorphin (Dyn) A as KOR selective peptide antagonists.11–13 In early studies on 
N-terminal alkylated analogs of [D-Pro10]Dyn A-(1-11) we found that despite its high 
affinity for KOR the N-benzyl analog displayed lower agonist potency than other N-alkyl 
derivatives in the guinea pig ileum (GPI) assay,14, 15 and produced partial agonism in the 
adenylyl cyclase assay.16 A series of (5,8) cyclic Dyn A(1-13)NH2 analogs with varying 
ring sizes synthesized in our laboratory also displayed very low agonist potencies in the GPI 
assay.17 When these structural modifications were combined we obtained the Dyn A-
(1-11)NH2 analog zyklophin (Figure 1) which exhibits high selectivity for KOR and is a 
KOR antagonist in the adenylyl cyclase assay. 18
Zyklophin was subsequently shown to also be a selective KOR antagonist in vivo with a 
finite duration of KOR antagonist activity (12-18 h) following systemic administration.19 
Following peripheral subcutaneous (s.c.) administration, zyklophin antagonized the 
antinociceptive activity of the centrally administered KOR agonist U50,488, suggesting that 
this peptide crossed the blood-brain barrier to act on KOR in the CNS.19 This peptide also 
suppressed stress-induced reinstatement of cocaine seeking behavior in mice following s.c. 
administration,19 suggesting its potential as a lead compound for the development of 
therapeutics for the treatment of cocaine addiction.
We are exploring the structure-activity relationships (SAR) of zyklophin in order to examine 
its potential interactions with KOR and to enhance its antagonist potency. We initially 
prepared linear [N-benzyl-Tyr1]Dyn A-(1-11)NH2 analogs 2 and 3 (Table 1) in which 
positions 5 and 8 were modified to assess their individual contributions to the activity of 
zyklophin. We expected that the D-amino acid in position 5 adjacent to the “message” 
sequence20 might affect the orientation of pharmacophoric groups in the receptor binding 
site and therefore could play a significant role in the antagonist activity of zyklophin, while 
the residue in position 8 was not expected to affect peptide efficacy. In this initial SAR study 
of cyclic analogs we made three types of modifications: to the N-terminal group (analogs 4–
8, Table 1), amino acid substitutions in the sequence (analogs 9–14), and to the cyclic 
constraint (analogs 15–17). We explored the effect of different N-terminal alkyl substituents 
on the receptor affinities and KOR activity of zyklophin, based on the hypothesis that the N-
terminal alkyl group could affect the interactions of the rest of the peptide with KOR and 
therefore the ability of zyklophin to bind to this receptor without activating it. We 
investigated the contribution of different residue side chains to the KOR affinity and 
antagonist activity of zyklophin by performing an Ala scan of the non-glycine residues of 
zyklophin (excluding residues 5 and 8) up through residue 9 (Table 1). (Previous studies of 
linear [N-benzyl]Dyn A(1-11)NH2 analogs suggested that modifications in the C-terminus 
did not affect peptide efficacy.21) In addition, to explore the importance of the phenolic 
group of Tyr1 on the activity of zyklophin we synthesized the Phe1 analog of zyklophin (14, 
Table 1). Finally, we explored the role of ring size and residues involved in the cyclic 
constraint on the KOR interaction of zyklophin.
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The synthesis of the zyklophin analogs involved synthesizing the N-terminal N-alkyl amino 
acid derivatives in solution and assembly of the peptides on the solid support. Following the 
solid phase synthesis of the (2-11) peptide fragments, the appropriate N-alkyl amino acid 
derivatives were coupled to the N-terminus to obtain the protected (1-11) peptides on resin. 
The final peptides were then obtained by cleavage from the resin.
Amino acid synthesis
Except for N-allyl-Tyr the N-alkyl amino acid derivatives were synthesized by reductive 
amination of the amino acid t-butyl ester with the appropriate aldehyde and sodium 
triacetoxyborohydride to yield the N-alkyl amino acid t-butyl ester, which was subsequently 
cleaved with 90% TFA and 10% water to yield the N-alkyl amino acid (Scheme 1a). N-allyl-
Tyr (Scheme 1c) was prepared by alkylating H-Tyr-OtBu with 1 equivalent of allyl bromide 
in the presence of N,N-diisopropylethylamine (DIEA) in DMF. Using only one equivalent of 
allyl bromide minimized formation of the diallyl compound; the desired monoallyl amino 
acid ester was separated from unreacted starting material by silica gel flash column 
chromatography using EtOAc/hexane. The t-butyl ester was subsequently cleaved with 90% 
TFA and 10% water.
The resulting N-alkyl amino acids, obtained as TFA salts, exhibited low solubility in DMF 
at room temperature and required heating to >85°C for solubilization (see below). While 
microwave couplings are routinely performed at ≥ 75°C, racemization at elevated 
temperatures could be a potential issue during coupling of the N-alkyl amino acids to the 
(2-11) fragments. Initially Fmoc protection of N-benzyl-Tyr-OtBu by treatment with Fmoc-
Cl was examined, but after removal of the t-butyl ester the resulting Fmoc-protected amino 
acid was not soluble in DCM or DMF at room temperature. Therefore selected N-alkyl-
amino acid derivatives with low solubility, namely N-CPM-Tyr-OtBu and N-benzyl-Phe-
OtBu, were protected with the Alloc (allyloxycarbonyl) group by treating with allyl 
chloroformate and DIEA in DCM to afford the Alloc-N-alkyl amino acid esters (Scheme 
1b); in the case of N-CPM-Tyr-OtBu the bis-Alloc derivative was obtained. The t-butyl 
esters were subsequently cleaved with 90% TFA/10% DCM to afford the Alloc-protected 
amino acids (Scheme 1b) which unlike the unprotected N-alkyl amino acids were readily 
soluble in DMF at room temperature. This avoided heating and potential racemization of the 
amino acids during coupling (see below).
Peptide synthesis
The peptides were synthesized using the Fmoc solid phase synthetic strategy. The (2-11) 
peptide fragments were assembled on a low load poly(ethylene glycol)-polystyrene (PEG-
PS) resin containing the peptide amide linker [PAL, 5-(4-aminomethyl-3,5-
dimethoxyphenoxy)valeric acid linker] using benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 1-hydroxybenzotriazole 
(HOBt) (4 equiv each) and DIEA (10 equiv) in DCM:DMF (1:1) to couple the Fmoc-amino 
acids (4 equiv) to the growing peptide chain using a custom manual multiple peptide 
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synthesizer.22 The side chain protecting groups used were 2,2,4,6,7-pentamethyl 
dihydrobenzofurane-5-sufonyl (Pbf) for Arg and Boc for Lys.
For the linear analogs 2 and 3 the (2-11) peptide precursors were synthesized similar to the 
above procedure with the side chains of D-Asn in peptide 2 and Dap (Dap = 2,3-
diaminopropionic acid) in peptide 3 protected by trityl (Trt) and 4-methyltrityl (Mtt) groups, 
respectively. For peptide 3 following the synthesis of the (2-11) linear fragment, the Mtt 
protecting group on Dap was selectively deprotected using 3% TFA and 5% 
triisopropylsilane (TIS) in DCM, and the resulting amine was acetylated using acetyl 
imidazole in DMF.
The (2-11) fragments of the cyclic peptides 4–9 and 14–17 were synthesized by a similar 
approach (see Scheme 2). The D-Asp and Dap residues in positions 5 and 8 were protected 
with the hyperacid labile 2-phenylisopropyl (Pip) and Mtt groups, respectively. Following 
the synthesis of the (5-11) fragments, the Pip and Mtt groups were deprotected by 3% TFA 
and 5% TIS in DCM. The selective deprotection of the Mtt group on residue 8 was 
monitored by acetylation of the resulting free amine by acetic anhydride or acetyl imidazole, 
followed by cleavage of an aliquot of resin and HPLC analysis of the resulting product. 
Subsequently, the carboxyl group of D-Asp5 and the amine of Dap8 were cyclized using 6-
chloro-benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate 
(PyClocK) and 1-hydroxy-7-azabenzotriazole (HOAt, 4 equiv each) with DIEA (10 equiv) 
in a mixture of DCM:DMF (1:1), generally for 20–24 h. The cyclizations were monitored 
using the qualitative ninhydrin test.23 As expected for syntheses performed on a low load 
resin, there was no evidence for cyclodimerization by mass spectrometry. Any remaining 
unreacted free amine of Dap was acetylated by treatment with acetyl imidazole and DIEA in 
DMF. Further extension of the peptide up to Gly2 afforded the (2-11) fragments of the cyclic 
peptides. For the synthesis of peptides 15 and 16 Dab(Mtt) (Dab = 2,3-diaminobutyric acid) 
and Orn(Mtt) (Orn = ornithine) were incorporated in position 8, respectively and for peptide 
17 L-Asp(Pip) was incorporated in position 5. In the case of these three peptides the 
cyclizations required longer reaction times (∼ 36 h) to go to completion.
Coupling of the N-alkyl amino acids
The coupling of the N-terminal amino acid derivatives to the resin-bound (2-11) peptide 
sequences was carried out using PyClocK, HOAt and DIEA in DMF. The solutions of the N-
alkyl amino acids required elevated temperatures (80–85°C for N-benzyl-Tyr and N-benzyl-
Ala and >100°C for the N-allyl and N-phenethyl Tyr derivatives) to obtain complete 
dissolution in DMF. For N-benzyl-Tyr and N-benzyl-Ala the solutions were cooled to room 
temperature prior to addition of the coupling reagents and base, but the solutions of N-allyl- 
and N-phenethyl-Tyr became turbid upon cooling; hence the coupling agents were added to 
these solutions while they were still hot, followed by cooling the solution, addition of the 
base, and coupling to the (2-11) fragment. In these cases where the unprotected N-terminal 
N-alkyl amino acid was coupled to the (2-11) peptides there was no evidence of 
incorporation of multiple N-alkyl amino acids (i.e. formation of 12-mer peptides); this is 
likely due to the steric hindrance of the bulky secondary amine and the low (2-fold) excess 
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of amino acid used in these reactions. N-CPM-Tyr-OH did not couple to the (2-11) 
fragment, probably due to its minimal solubility in DMF.
N-CPM-Tyr-OH and N-benzyl-Phe-OH were coupled as their N-protected derivatives which 
are soluble in DMF at room temperature. Following coupling of the unprotected N-benzyl-
Phe-OH to the (2-11) fragment, the crude peptide 14 showed a second peak in the HPLC 
(Figure 3a). ESI analysis of the peptide mixture did not show formation of a higher 
molecular weight species (i.e. the 12-mer peptide), suggesting that the second peak resulted 
from N-benzyl-Phe-OH undergoing racemization during activation of the amino acid or 
subsequent coupling to the (2-11) fragment. To avoid potential epimerization and enhance 
their solubility, the Alloc-protected derivative of N-benzyl-Phe-OH, as well as N-CPM-Tyr-
OH, were prepared as described above. Following coupling of the Alloc derivatives to the 
(2-11) peptide fragment on the resin, the Alloc group was removed by Pd(0) and 
phenylsilane.24 To synthesize peptide 4, Fmoc-MeTyr(OtBu)-OH was coupled to the (2-11) 
peptide fragment, followed by Fmoc deprotection. In the case of peptide 8, Fmoc-
Tyr(OtBu)-OH was coupled to the (2-11) peptide fragment by the standard coupling 
procedure, followed by Fmoc deprotection and subsequent acylation of the N-terminal of 
Tyr with benzoic anhydride in the presence of DIEA in DMF.
Investigation of potential racemization of the N-terminal residue of zyklophin and analog 
14 by HPLC
Because dissolution of the N-alkyl amino acids required elevated temperatures, the peptides 
were examined by HPLC for potential epimerization of the N-terminal residue. To verify 
that the diastereomeric peptides could be separated by HPLC we synthesized [N-benzyl-D-
Tyr1]zyklophin. N-Benzyl-D-Tyr-OH was synthesized as described above (Scheme 1a) and 
coupled to the (2-11) fragment to give the N-benzyl-D-Tyr isomer of zyklophin. While a 
reversed phase HPLC (RP-HPLC) system using a slow gradient of aqueous acetonitrile 
containing TFA (10–25% over 30 min) did not adequately resolve the diastereomeric 
mixture of zyklophin and [N-benzyl-D-Tyr1]zyklophin (Figure 2a), a solvent system using 
aqueous 0.09M triethylammonium phosphate (TEAP, pH = 2.5)25 in acetonitrile (1–21% 
over 40 min) did provide baseline resolution of the diastereomers of zyklophin (Figure 2b) 
with the D-Tyr diastereomer eluting before zyklophin. Zyklophin synthesized by the 
standard procedure involving solubilization of N-benzyl-Tyr at 85°C did not show 
detectable epimerization when analyzed using the TEAP solvent system (Figure 2c). This 
HPLC solvent system was used to detect potential epimerization of the N-terminal residue 
during the synthesis of other zyklophin analogs. None of the peptides analyzed using this 
system (Table 2) except for peptide 14 showed evidence of epimerization of the N-terminal 
residue.
The Phe1 analog of zyklophin 14, however, showed evidence of epimerization of the N-
terminal residue when synthesized by the standard procedure in which N-benzyl-Phe in 
DMF was dissolved at 75–80°C prior to coupling to the (2-11) peptide fragment. Analysis of 
the crude peptide in the TEAP solvent system (Figure 3a) showed a mixture of two peaks, 
peak A (tR = 18.3 min, 17.5%) and peak B (tR = 20.3 min , 82.5%), for the peptide 
synthesized by this standard method. However, when synthesized using Alloc-N-benzyl-
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Phe, peptide 14 did not show detectable epimerization of the N-terminal residue; only peak 
B (tR = 20.3 min) was observed in the chromatogram (Figure 3b).
The peptides were purified by preparative RP-HPLC and analyzed by ESI-MS and 
analytical RP-HPLC. The final purity of all of the peptides by all methods was ≥ 98% (Table 
2).
Pharmacological results
The peptides were evaluated for receptor affinities in radioligand binding assays using 
Chinese hamster ovary (CHO) cells stably expressing opioid receptors (Table 3). Zyklophin 
showed somewhat lower KOR affinity in the radioligand binding assay than obtained 
originally (Ki = 30.3 nM).18 Similarly, the KOR binding affinity of Dyn A(1-11)NH2 (Ki = 
2.6 ± 0.3 nM) was also lower than found previously (Ki = 0.57 ± 0.01 nM),18 possibly due to 
subtle differences in assay conditions (e.g. differences in the radioligand, filtration rate, 
etc.). The MOR affinity found here for zyklophin was similar to that reported previously.18
In order to assess the individual contributions of the residues in positions 5 and 8 of 
zyklophin the linear peptides 2 and 3 were synthesized. Previously we found that the linear 
zyklophin analog [N-benzyl-Tyr1,D-Asn5,Dap(Ac)8]Dyn A(1-11)NH2 with substitutions in 
both positions exhibited KOR affinity 2-fold lower (Ki = 66.9 nM) than zyklophin and 8-
fold lower than Dyn A(1-11)NH2.18, 21 When the peptides with a single modification were 
evaluated we found that peptide 2 had 4-fold lower KOR affinity (Ki = 412 nM) compared 
to zyklophin (Ki = 95.2 nM), while peptide 3 exhibited 3-fold higher KOR affinity (Ki = 28 
nM). These results suggest that the residue in position 5 had a much larger influence on the 
KOR affinity of zyklophin than the amino acid in position 8. While zyklophin has a D-Asp 
involved in the lactam linkage at position 5, peptide 3 has L-Leu in this position as found in 
the endogenous Dyn A. Hence, the side chain of the residue at position 5 and/or changes in 
the backbone conformation of the peptide due to the different configuration at residue 5 
influenced the KOR affinity of the zyklophin analogs. While peptide 2 had low MOR 
affinity (Ki = 2440 nM), peptide 3 had 28-fold higher MOR affinity (Ki = 157 nM) than 
zyklophin (Ki = 4380 nM), suggesting that residue 5 is important for the low MOR affinity 
of zyklophin. Both linear analogs 2 and 3 displayed similar selectivities for KOR vs. MOR 
that were lower than that of zyklophin.
Sterically diverse alkyl groups ranging from methyl to phenethyl were incorporated at the N-
terminus to examine their effect on the affinity, efficacy and potency of the zyklophin 
analogs. Peptides 4, 6 and 7 had similar to slightly higher KOR affinities (Ki = 44–160 nM) 
than zyklophin, suggesting that these N-alkyl modifications are tolerated in the KOR binding 
site. The N-allyl analog 5 had the lowest KOR affinity (Ki = 326 nM) among the N-alkylated 
analogs examined. The N-benzoyl derivative 8 showed only somewhat lower (3.6-fold) 
KOR affinity (Ki = 346 nM) compared to zyklophin, indicating that a basic secondary amine 
at the N-terminus is not essential for maintaining the KOR affinity of zyklophin analogs. All 
of the analogs displayed low MOR affinity (Ki >1 µM) similar to zyklophin (only the N-
methyl derivative 4 displayed increased MOR affinity (Ki = 1490 nM) compared to 
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zyklophin). The increased KOR affinity of analogs 6 and 7 resulted in increases in their 
KOR vs. MOR selectivities (Ki ratios (MOR/KOR) = 245 and 137), respectively.
An alanine scan of zyklophin of the non-glycine residues up through position 9, excluding 
the residues in positions 5 and 8 involved in the lactam, was also performed to identify 
residues important for the KOR affinity of zyklophin. Unexpectedly the Ala1 analog 9 
displayed only a 5-fold decrease in the KOR affinity (Ki = 516 nM) compared to zyklophin, 
suggesting that Tyr in position 1, while making some contribution to its affinity, is not 
critical for zyklophin’s binding to KOR. Alanine substituted analogs 10 (Ala4) and 11 (Ala6) 
showed the largest decreases, 42- and 18-fold (Ki = 4010 and 1750 nM, respectively), 
respectively, in KOR affinity compared to zyklophin, indicating that the Phe4 and the Arg in 
position 6 are critical for maintaining the KOR affinity of zyklophin. Interestingly, peptide 
12 (Ala7) showed only a 3-fold decrease in KOR affinity (Ki = 293 nM), a much smaller 
decrease than seen for substitution of Arg6, suggesting that Arg7 makes only a minor 
contribution to the KOR affinity of zyklophin. Analog 13 (Ala9) displayed KOR affinity (Ki 
= 168 nM) within 2-fold of zyklophin, indicating that this positively charged residue is not 
important for the KOR affinity of zyklophin. Analogs 9–13 all displayed low affinity for 
MOR (Ki > 2 µM) similar to zyklophin.
The alanine scan of Dyn A(1-13) performed previously26 revealed that within the Leu-
enkephalin core of the peptide Ala1 and Ala4 substitution caused dramatic decreases in 
opioid receptor affinities, indicating that Tyr1 and Phe4 residues were critical for opioid 
receptor binding affinity. Outside the Leu-enkephalin core of Dyn A(1-13), the Ala6 and 
Ala7 analogs showed the largest decreases (3- to 7-fold) in binding affinities, suggesting that 
Arg6 and Arg7 contribute to the opioid receptor affinity of Dyn A(1-13). Ala9 and Ala11 
analogs showed small decreases (2- to 3-fold) in opioid receptor binding affinity, suggesting 
that these residues made minor contributions to the opioid receptor affinity of Dyn 
A(1-13).26
Comparison of the alanine scan results for Dyn A(1-13) and zyklophin reveals significant 
differences in the contributions of some of the residues to the KOR affinities of these two 
peptides. While Tyr1 was critical in maintaining the opioid receptor affinity of Dyn A(1-13), 
it appeared to make a relatively minor contribution to the KOR binding affinity of 
zyklophin. Phe4, however, was critical for both the opioid receptor affinity of Dyn A(1-13) 
and the KOR affinity of zyklophin. Arg6 contributed to both the opioid receptor affinity of 
Dyn A(1-13) and the KOR affinity of zyklophin, although the impact of substituting Ala for 
Arg6 in zyklophin appeared to be greater (18-fold decrease) than the substitution of the same 
amino acid in Dyn A(1-13) (7-fold decrease). Arg7 appeared to make a minor contribution to 
both the opioid receptor affinity of Dyn A(1-13) and the KOR affinity of zyklophin, while 
Arg9 residue did not appear to contribute significantly to the binding affinities of either 
peptide. The differences in the results for the alanine scan analogs of the two peptides 
suggest differences in the binding interactions with the kappa opioid receptor. Some 
differences in receptor interactions would be expected since Dyn A(1-13) is a KOR agonist 
while zyklophin is a KOR antagonist. Differences in the radioligand binding assays used to 
evaluate the Ala-substituted analogs of the two peptides, however, limit the comparisons 
that can be made. The Dyn A(1-13) analogs were evaluated in radioligand binding assays 
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performed in rat brain homogenates, which contain MOR and delta opioid receptor (DOR) 
but relatively low levels of KOR,27 using the non-selective radioligand [3H]etorphine, so 
that the affinities of the analogs for individual opioid receptors cannot be assessed from 
those data.
The N-benzyl-Phe1 analog 14 was also synthesized and displayed a slight increase in KOR 
affinity (Ki = 69 nM) compared to zyklophin, verifying that the phenol of N-terminal Tyr1 
does not contribute to the affinity of zyklophin for KOR. This is in contrast to Dyn 
A(1-11)NH2 where substitution of Tyr1 by Phe resulted in a 23-fold decrease in KOR 
affinity,28 demonstrating that the phenol of Tyr is critical for the KOR affinity of this 
agonist. Peptide 14 also exhibited 3.5-fold higher selectivity for KOR over MOR compared 
to zyklophin.
Changes in the lactam ring of zyklophin had a minor effect on KOR and MOR affinities. 
Peptides 15 and 16 with larger ring sizes than zyklophin had KOR affinities 2- to 4-fold 
lower (Ki = 403 and 222 nM for peptides 15 and 16, respectively) than zyklophin. Peptide 
17 containing L-Asp in position 5 also showed 4-fold lower KOR affinity (Ki = 410 nM); 
thus a change in the configuration of this amino acid was reasonably well tolerated by KOR 
without a large loss in affinity. Similar to zyklophin, analogs 15–17 all displayed low 
(micromolar) affinity for MOR. However, the KOR vs. MOR selectivity varied depending 
on the analog, with analogs 15 and 17 exhibiting lower (6- to 8-fold) and analog 16 similar 
(37-fold) selectivities compared to zyklophin (46-fold in these assays).
Only the linear peptide 3 exhibited any appreciable affinity for DOR (Ki = 2290 ± 520 nM). 
All of the remaining peptides exhibited minimal DOR affinity.
The efficacies of the zyklophin analogs were evaluated in the agonist stimulated GTPγS 
binding assay. All of the cyclic peptides displayed negligible efficacy (<15%) when 
screened at 10 µM in this assay. Our hypothesis was that the N-terminal alkyl group might 
shift the peptide in the KOR binding site, thereby changing interactions of other parts of the 
peptide with the receptor and preventing the peptide from activating the receptor. Among 
the N-alkyl analogs, peptide 4 with an N-methyl substitution was expected to cause minimal 
shift of the peptide in its binding site and hence exhibit agonist activity, but this was not the 
case. The negligible efficacy of peptides 4–8 and 15–17 in the GTPγS assay suggest that 
changes in the N-terminal alkyl group, ring size or residue 5 configuration did not increase 
efficacy compared to zyklophin. As expected, none of the alanine-substituted analogs 
exhibited appreciable efficacy in this assay, nor did the Phe1 analog 14. Only the linear 
peptide 3 exhibited partial agonist activity at KOR in the GTPγS assay (26% efficacy 
compared to the full agonist Dyn A(1-13)NH2, EC50 = 39.5 ± 17.4 nM); these results are 
consistent with those found for [N-benzyl-Tyr1]Dyn A(1-11)NH2 in the adenylyl cyclase 
assay.21
The KOR antagonist potency of selected analogs was analyzed in the GTPγS assay by 
Schild analysis against Dyn A(1-13)-NH2 as the KOR agonist29 (Figure 4, Table 4). The 
potency of zyklophin as a KOR antagonist in the GTPγS assay was consistent with its KOR 
affinity, but somewhat lower than that found previously in the adenylyl cyclase assay (KB = 
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84 nM).21 The N-CPM peptide 6 showed potent antagonism in this assay, 28-fold higher 
than zyklophin, and the N-phenethyl peptide 7 exhibited reasonable antagonist potency. The 
Phe1 peptide 14 also exhibited potent KOR antagonism, consistent with its binding affinity, 
indicating that the Tyr phenol is not required for the KOR antagonist potency of zyklophin. 
The Ala7 analog 12 did not antagonize KOR, consistent with its lower KOR affinity.
Conclusions
Various linear and cyclic analogs of zyklophin were synthesized in order to examine the 
SAR of this peptide for KOR interaction and antagonism. During the synthesis there was 
potential for epimerization of the N-terminal residue because solutions of the N-alkyl amino 
acid required heating to obtain complete dissolution. An HPLC solvent system that could 
resolve the diastereomers of zyklophin was identified and used to examine the peptides for 
potential racemization of the N-terminal residue. Only in the case of N-benzyl-Phe was 
evidence of epimerization detected. These results are not surprising since elevated 
temperatures (typically 75 °C) are routinely used in microwave-assisted amino acid 
couplings in peptide synthesis, and phenylalanine is well known to be prone to racemization. 
To avoid potential epimerization of N-benzyl-Phe and to increase the solubility of N-CPM-
Tyr the Alloc derivatives, which were readily soluble at room temperature, were prepared; 
this eliminated the epimerization of N-benzyl-Phe and increased the yield of the N-CPM-
Tyr1 peptide 6.
The in vitro pharmacological evaluation of the linear and the cyclic zyklophin analogs 
provided initial SAR for the lead peptide zyklophin. The receptor affinities of the linear 
analogs 2 and 3 suggested that the residue at position 5 has a greater influence on the opioid 
receptor affinities of zyklophin than residue 8. The L-configuration and/or the hydrophobic 
side chain of Leu in position 5 of peptide 3 likely contributes to the higher KOR and MOR 
affinities of this peptide. However, the KOR affinity of the cyclic analog 17 with an L-Asp 
at position 5 suggested that the configuration of residue 5 has a minor influence on the KOR 
affinity of cyclic zyklophin analogs. The N-phenethyl and the N-CPM substitutions resulted 
in a slightly higher (1.5- to 2-fold) affinity for KOR than zyklophin, while the other N-
terminal modifications and ring variations were also well tolerated. The basic amine at the 
N-terminus of zyklophin is not necessary for maintaining the KOR affinity of zyklophin, as 
shown by the relatively modest reduction in KOR affinity of the N-benzoyl analog 8 
compared to zyklophin. These results are consistent with other peptide KOR antagonists 
based on dynorphin identified in our laboratory.11–13 The pharmacological results for 
alanine substituted analogs indicate that Phe4 and Arg6 are critical for zyklophin’s KOR 
affinity. Interestingly, the Tyr1 residue makes a relatively minor contribution to the KOR 
affinity of zyklophin based on the results for the N-benzyl-Ala1 analog, and the similar KOR 
affinity of the N-benzyl-Phe1 analog to zyklophin indicates that the phenol of Tyr does not 
contribute to the KOR affinity of zyklophin. While the loss of KOR affinity with Ala 
substitution of Phe4 is similar to that found for Dyn A(1-13),26 the minimal effect of 
substitution by Ala or Phe in position 1 are in marked contrast to the effects in Dyn A(1-13) 
and Dyn A(1-11)NH2.26,28 Substitution of Ala at postion 6 markedly decreased KOR 
affinity, while replacement of residue 7 had a much smaller effect on KOR affinity, 
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indicating that a basic residue in position 6 is much more important for the KOR affinity of 
zyklophin than is one in position 7. As expected, the Ala9 analog displayed affinity 
comparable to zyklophin, indicating a basic residue at position 9 is not important for the 
maintaining the KOR affinity of zyklophin.
The results from the agonist stimulated GTPγS assays indicate that all of the zyklophin 
analogs synthesized in the present study, except for the linear peptide 3, exhibited negligible 
efficacy (< 15% compared to full agonist Dyn A(1-11)NH2) similar to zyklophin. Schild 
analysis of the analogs with the highest KOR affinities found that the N-phenethyl-Tyr1, N-
CPM-Tyr1 and the N-benzyl-Phe1 analogs were more potent KOR antagonists than 
zyklophin in this assay. These analogs appear to be promising compounds for additional 
studies towards the potential development of potent peptide KOR antagonists. Further 
studies of selected zyklophin analogs are underway in our laboratory.
Experimental section
Materials
Fmoc-protected PAL-PEG-PS resin was purchased from Applied Biosystems (Foster City, 
CA). Standard Fmoc-protected amino acids were obtained from EMD Biosciences 
(Gibbstown, NJ) and Peptides International (Louisville, KY), Fmoc-D-Asp(Pip)OH was 
obtained from Bachem (King of Prussia, PA), and Fmoc-Dap(Mtt)OH, Fmoc-Dab(Mtt)-OH 
and Fmoc-Orn(Mtt)-OH were obtained from EMD Biosciences. Fmoc-NMe-Tyr(OtBu)-OH 
was obtained from APPTec (Louisville, KY), and Tyr-OtBu was obtained from EMD 
Biosciences. PyBOP and PyClocK were purchased from EMD Biosciences. HOBt was 
purchased from Peptides International, and DIEA was from Fisher Scientific (Fair Lawn, 
NJ). Piperidine, THF and anhydrous acetonitrile (SureSeal) were purchased from Sigma-
Aldrich (St. Louis, MO). All HPLC-grade solvents (acetonitrile, DMF, DCM, EtOAc, 
hexane and methanol) used for amino acid and peptide synthesis or HPLC analysis were 
obtained from Fisher Scientific. TFA for HPLC purification and analysis was purchased 
from Pierce (Rockford, IL); benzaldehyde and sodium cyanoborohydride from Sigma-
Aldrich; and phenylacetaldehyde, allyl bromide, allyl chloroformate and TIS were from 
Acros Organics (Fairlawn, NJ).
Amino acid synthesis
General procedure for N-alkyl-Tyr-OH synthesis—The amino acid t-butyl ester (1 
equiv) and NaBH(OAc)3 (1 equiv) were dissolved in anhydrous acetonitrile (SureSeal, 5–10 
mL/mmol), followed by the addition of the corresponding aldehyde (1.5 equiv) and a 
catalytic amount of glacial acetic acid (0.2 mL). The reaction was performed under N2 for 
12–18 h at room temperature with continuous stirring. The reaction was monitored by TLC 
(1:2 EtOAc:hexane plus 1 drop NEt3). After completion of the reaction the acetonitrile was 
evaporated in vacuo, the pH adjusted to 7.0 with saturated NaHCO3, and the aqueous layer 
extracted with EtOAc (3 × 10 mL). The combined EtOAc extracts were washed with water, 
and the organic layer was dried (MgSO4) and evaporated under reduced pressure to obtain 
crude N-alkyl-Tyr-OtBu that was purified by flash silica gel column chromatography (20–
30% EtOAc in hexane). The N-alkyl-Tyr-OtBu was analyzed for purity by HPLC using a 
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gradient of 5–50% aqueous acetonitrile with 0.1% TFA over 45 min at a flow rate of 1 mL/
min. The t-butyl ester on the purified N-alkyl-Tyr-OtBu was cleaved by 90% TFA plus 10% 
water (8–10 mL/mmol) for 12 h. The reaction mixture was concentrated in vacuo, and the 
desired product was obtained by precipitation with diethyl ether.
N-Benzyl-Tyr-OH (23a)—Tyr-OtBu (0.474 g, 2.0 mmol, 1 equiv) was reacted with 
benzaldehyde and NaBH(OAc)3 in anhydrous acetonitrile (12 mL) for 18 h. The crude 
product was isolated as described above, and pure N-benzyl-Tyr-OtBu (520 mg, 80%) was 
obtained following flash silica gel column chromatography (25% EtOAc/hexane) as an off-
white amorphous solid: ESI-MS m/z [M+H]+ 328.1913 (calcd), 328.1784 (observed); 
HPLC: tR 24.3 min (purity 100%); 1H NMR (500 MHz, d6-acetone) δ 8.14 (s, 1H), 7.35 – 
7.15 (m, 5H), 7.04 (d, J = 8.2 Hz, 2H), 6.74 (d, J = 8.7 Hz, 2H), 3.82 (d, J = 13.3 Hz, 1H), 
3.64 (d, J = 13.3 Hz, 1H), 3.30 (t, J = 6.8 Hz, 1H), 2.88 – 2.71 (m, 2H), 1.38 (s, 9H); 13C 
NMR (126 MHz, CDCl3) δ 171.90, 153.14, 136.83, 128.38, 126.42, 126.38, 125.96, 125.20, 
113.40, 79.60, 60.52, 49.84, 36.56, 25.98.
N-Benzyl-Tyr-OtBu (200 mg) was cleaved to the corresponding acid using TFA as 
described above to yield N-benzyl-Tyr-OH (160 mg, 68%) as a white amorphous powder: 
ESI-MS m/z [M+H]+ 272.1287 (calcd), 272.1227 (observed).
N-Benzyl-D-Tyr-OH (23b)—D-Tyr-OtBu (0.118 g, 0.5 mmol, 1 equiv) and NaBH(OAc)3 
in anhydrous acetonitrile (5 mL) were reacted with benzaldehyde for 18 h. Pure N-benzyl-D-
Tyr-OtBu (90 mg, 55%) was obtained following flash silica gel column chromatography 
(20% EtOAc/hexane) as an off-white amorphous solid: ESI-MS m/z [M+H]+ 328.1913 
(calcd), 328.1890 (observed); 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.17 (m, 5H), 6.97 (d, J 
= 8.4 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 3.80 (d, J = 12.8 Hz, 1H), 3.66 (d, J = 12.8 Hz, 1H), 
3.42 (t, J = 6.9 Hz, 1H), 2.95 – 2.77 (m, 2H), 1.39 (s, 1H); 13C NMR (126 MHz, CDCl3) δ 
172.36, 153.37, 137.44, 128.83, 126.84, 126.74, 126.67, 125.59, 113.75, 79.98, 60.98, 
50.29, 37.03, 26.43.
N-Benzyl-D-Tyr-OtBu (90 mg) was cleaved with TFA as described above to yield N-
benzyl-D-Tyr-OH (51 mg, 49%) as a white amorphous powder: ESI-MS m/z [M+H]+ 
272.1287 (calcd), 272.1251 (observed).
N-Phenethyl-Tyr-OH (24)—Treatment of Tyr-OtBu (0.474 g, 2.0 mmol, 1 equiv) with 
NaBH(OAc)3 and phenyl acetaldehyde in anhydrous acetonitrile (10 mL) for 16 h yielded 
pure N-phenethyl-Tyr-OtBu (452 mg, 66%) as an off-white oil following flash silica gel 
column chromatography (25% EtOAc in hexane): ESI-MS m/z [M+H]+ 342.2069 (calcd), 
342.2004 (observed); HPLC: tR 27.9 min (purity 100%); 1H NMR (500 MHz, d6-acetone) δ 
8.13 (s, 1H), 7.32 – 7.11 (m, 5H), 7.04 (d, J = 8.5 Hz, 2H), 6.74 (d, J = 8.5 Hz, 2H), 3.31 
(dd, J = 6.4 and 7.6 Hz, 1H), 2.83 – 2.68 (m, 6H), 1.34 (s, 9H); 13C NMR (126 MHz, d6-
acetone) δ 174.49, 156.89, 141.43, 131.36, 129.64, 129.18, 126.82, 115.77, 80.84, 64.77, 
50.22, 39.67, 37.42, 28.25.
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N-Phenethyl-Tyr-OtBu (165 mg) was cleaved to afford the corresponding acid 24 (125 mg, 
65%) as a yellowish-white solid: ESI-MS m/z [M+H]+ 286.1443 (calcd), 286.1432 
(observed).
N-Benzyl-Ala-OH (25)—Ala-OtBu HCl (0.43 g, 2.4 mmol, 1.2 equiv) and benzaldehyde 
(0.2 mL, 2.0 mmol, 1 equiv) were dissolved in CHCl3 (10 mL), followed by addition of a 
solution of NaBH(OAc)3 (0.63 g, 3 mmol, 1.5 equiv) in CHCl3 (5 mL). The reaction 
mixture was stirred at rt for 12 h, water (20 mL) was added, the aqueous layer was separated 
and extracted with additional CHCl3 (2 × 20 mL). The combined CHCl3 layers were washed 
with water (20 mL), dried over MgSO4 and the solvent evaporated to obtain the product 
which was purified by flash silica gel column chromatography (15% EtOAc /hexane) to give 
N-benzyl-Ala-OtBu (220 mg, 39%) as a white semisolid: ESI-MS m/z [M+H]+ 236.1651 
(calcd), 236.1628 (observed); HPLC: tR 13.08 min (purity 95.8%) ;1H NMR (500 MHz, 
CDCl3) δ 7.39 – 7.23 (m, 5H), 3.82 (d, J = 12.7 Hz, 1H), 3.68 (d, J = 12.7 Hz, 1H), 3.27 (q, 
J = 7.0 Hz, 1H), 1.86 (s, 1H), 1.51 (s, 9H), 1.30 (d, J = 7.0 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 175.37, 140.14, 128.59, 128.45, 127.19, 81.07, 56.86, 52.15, 28.29, 19.35.
N-Benzyl-Ala-OtBu (120 mg) was cleaved to afford the corresponding acid as a yellowish-
white solid (75 mg, 50%): ESI-MS m/z [M+H]+ 180.1025 (calcd), 180.1009 (observed).
N-CPM-Tyr-OtBu (27)—Tyr-OtBu (0.237 g, 1.0 mmol, 1 equiv) was reacted with 
cyclopropylcarboxaldehyde and NaBH(OAc)3 in anhydrous acetonitrile (7 mL) for 12 h, and 
purified by flash silica gel column chromatography (30% EtOAc in hexane) to give N-CPM-
Tyr-OtBu (160 mg, 55%) as a white powder: ESI-MS m/z [M+H]+ 292.1913 (calcd), 
292.1819 (observed); HPLC: tR 19.10 min (purity 97.4%); 1H NMR (500 MHz, d6-acetone) 
8.05 (s, 1H), 6.97 (dd, J = 6.5, 2.0 Hz, 2H), 6.65 (dd, J = 6.5, 2.1 Hz, 2H), 3.22 (dd, J = 7.6, 
6.3 Hz, 1H), 2.79 – 2.67 (m, 1H), 2.66 – 2.59 (m, 1H), 2.38 (dd, J = 11.7, 6.1 Hz, 1H), 2.21 
(dd, J = 11.7, 7.2 Hz, 1H), 1.26 (s, 9H), 0.82 – 0.72 (m, 1H), 0.35 – 0.27 (m, 2H), 0.05-0.01 
(dd, J = 4.8, 1.8 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ 174.11, 155.11, 130.60, 128.73, 
115.55, 81.53, 63.38, 53.28, 38.99, 28.23, 11.10, 3.86, 3.46.
Alloc-N-CPM-Tyr(Alloc)-OH (31)—N-CPM-Tyr-OtBu (0.08 g, 0.27 mmol, 1 equiv) in 
anhydrous DCM (2.5 mL) was treated with allyl chloroformate (0.117 mL, 1.08 mmol, 4 
equiv) and DIEA (0.189 mL, 1.08 mmol, 4 equiv) for 12 h at room temperature. The DCM 
was evaporated in vacuo, EtOAc (10 mL) was added, and the solution washed with water 
(10 mL). Following back-extraction of the aqueous layer with additional EtOAc (10 mL), 
the combined EtOAc fractions were washed with water (10 mL), dried (MgSO4) and 
evaporated in vacuo to afford the product 29 (91 mg, 73%) as a yellowish white semisolid: 
ESI-MS m/z [M+Na]+ 482.2155 (calcd), 482.2087 (observed); HPLC tR 18.51 min (25–95% 
of aqueous acetonitrile with 0.1 %TFA over 35 min, purity 95.4%); 1H NMR (500 MHz, 
CDCl3, 50 °C) δ 7.22 – 7.14 (m, 2H), 7.07 (d, J = 8.5 Hz, 2H), 6.03 – 5.87 (m, 2H), 5.46 – 
5.18 (m, 4H), 4.74 – 4.48 (m, 4H), 4.08 (m, 1H), 3.23 (m, 3H), 2.56 (m, 1H), 1.44 (s, 9H), 
0.69 (m, 2H), 0.35 (m, 2H), 0.05 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 169.97, 155.99, 
153.61, 150.25, 136.79, 131.57, 130.48, 121.02, 119.34, 81.73, 69.17, 66.30, 63.35, 53.64, 
29.86, 28.24, 10.34, 4.19, 3.83.
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The ester was cleaved with 90% TFA/10% DCM for 12 h at room temperature. The TFA 
was evaporated, and EtOAc (10 mL) and water (10 mL) were added. The aqueous layer was 
extracted with EtOAc (10 mL), and the combined organic extracts were washed with water 
(10 mL), dried with MgSO4 and evaporated in vacuo to yield the product (75 mg, 94%) as a 
yellowish white semisolid: ESI-MS m/z (M+K)+ 442.1268. (calcd), 442.1250 (observed); 
HPLC: tR 12.05 min (25–95% aqueous acetonitrile with 0.1 % TFA over 35 min, purity 
94.5%).
N-Benzyl Phe-O t Bu (28)—A solution of NaBH(OAc)3 (1.5 equiv) in CHCl3 (2 mL) 
was added to a solution of H-Phe-OtBu HCl (0.618 g, 2.4 mmol, 1.2 equiv) and 
benzaldehyde (1 equiv) in CHCl3 (5 mL), and the reaction mixture stirred at room 
temperature for 12 h. Water (20 mL) was added, and the aqueous layer extracted with 
additional CHCl3 (3 × 20 mL). The combined CHCl3 extracts were washed with water (20 
mL) and dried over MgSO4, and the crude product was purified by flash silica gel column 
chromatography (5–10% EtOAc in hexane) to give 28 (335 mg, 44%) as a white semisolid: 
ESI-MS m/z [M+H]+ 312.1964 (calcd), 312.1853 (observed); HPLC: tR 28.96 min (purity 
99.1%); 1H NMR (500 MHz, CDCl3) δ 7.31 – 7.18 (m, 10H), 3.86 (d, J = 13.0 Hz, 1H), 
3.73 (d, J = 13.0 Hz, 1H), 3.51 (dd, J = 7.6 and 6.6 Hz, 1H), 3.00 (dd, J = 13.6 and 6.5 Hz, 
1H), 2.91 (dd, J = 13.6 and 7.7 Hz, 1H), 1.35 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 
172.82, 138.19, 136.99, 129.47, 128.53, 128.49, 128.31, 127.45, 126.70, 81.65, 62.23, 
51.65, 39.21, 27.97.
Alloc-N-benzyl-Phe-OH (32)—N-Benzyl-Phe-OtBu (0.25 g, 0.8 mmol, 1 equiv) in 
anhydrous DCM (2 mL) was treated with allyl chloroformate (0.169 mL, 1.6 mmol, 2 equiv) 
and DIEA (0.278 mL, 1.6 mmol, 2 equiv) for 12 h. Alloc-N-benzyl-Phe-OtBu (208 mg, 
65%) was isolated as a yellowish semisolid as described above for Alloc-N-CPM-
Tyr(Alloc)-OtBu: ESI-MS (m/z) [M+Na]+ 418.1994 (calcd), 418.2047; HPLC: tR 18.68 min 
(25–95% aqueous acetonitrile with 0.1 % TFA over 35 min, purity 96.5%); 1H NMR (500 
MHz, CDCl3, 50°C) δ 7.32 – 7.21 (m, J = 7.0 Hz, 6H), 7.21 – 7.05 (m, 4H), 6.05 – 5.89 (m, 
1H), 5.28 (m, 2H), 4.82 – 4.52 (m, 3H), 4.16 (m, 1H), 3.99 – 3.82 (m, J = 13.4 Hz, 1H), 3.32 
(dd, J = 14.0, 5.8 Hz, 1H), 3.16 (dd, J = 14.0, 5.8 Hz, 1H), 1.39 (s, 9H); 13C NMR (126 
MHz, CDCl3) δ 169.47, 156.03, 138.33, 137.51, 132.81, 129.21, 128.33, 128.13, 127.07, 
126.36, 117.50, 81.49, 66.26, 62.40, 51.77, 36.24, 27.86.
The ester (120 mg) was cleaved with 90% TFA/10% DCM for 12 h at room temperature and 
isolated as described above for 31 to yield the acid 32 (100 mg, 98%) as a yellowish white 
semisolid: ESI-MS m/z (M+Na)+ 362.1368 (calcd), 362.1347 (observed); HPLC: tR 12.14 
min (25–95% aqueous acetonitrile with 0.1 % TFA over 35 min, purity 100%).
N-Allyl-Tyr-OH (34)—Tyr-OtBu (0.237 g, 1.0 mmol, 1 equiv) in DMF (2 mL) was cooled 
to 0–4 °C, and DIEA (0.174 mL, 1.0 mmol, 1 equiv) was added, followed by slow addition 
of allyl bromide (0.086 mL, 1 mmol, 1 equiv). The progress of the reaction was monitored 
by TLC (1:3 EtOAc:hexane plus 2 drops NEt3). After 45 h at room temperature under N2 a 
negligible amount of diallyl product was visible on TLC, while a substantial amount of 
residual starting material was present. The DMF was then removed in vacuo, and the crude 
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product purified by flash silica gel column chromatography (22% EtOAc/hexane) to give N-
allyl-Tyr-OtBu (80 mg, 29%) as a white solid powder: ESI-MS (m/z) [M-tBu]+ 222.1130 
(calcd), 222.1083 (observed); HPLC: tR 15.91 min (purity 100%); 1H NMR (500 MHz, d6-
acetone) δ 8.19 (s, 1H), 7.05 (d, J = 8.1 Hz, 2H), 6.75 (d, J = 8.3 Hz, 2H), 5.82 (m, 1H), 5.15 
(dd, J = 17.2 and 1.3 Hz, 1H), 5.01 (d, J = 10.2 Hz, 1H), 3.31 (t, J = 6.9 Hz, 1H), 3.19 (ddd, 
J = 77.8, 14.2, 5.9 Hz, 2H), 2.79 (ddd, J = 21.1, 13.5, 6.9 Hz, 2H), 1.37 (s, 9H); 13C NMR 
(126 MHz, d6-acetone) δ 174.52, 156.89, 138.10, 131.35, 129.53, 115.85, 115.76, 80.94, 
63.75, 51.09, 39.67, 28.26.
Pure N-allyl-Tyr-OtBu (80 mg) was deprotected as described above to obtain N-allyl-Tyr-
OH (43 mg, 44%) as a white powder: ESI-MS (m/z) [M+H]+ 222.1130 (calcd), 222.1060 
(observed).
Peptide synthesis
General procedures for solid phase peptide synthesis
Synthesis of (2-11) peptide fragments: The peptides were assembled on a low load Fmoc-
PAL-PEG-PS resin (0.19 mmol/g). Following removal of the Fmoc group from the resin 
(200 mg, 0.038 mmol) using 20% piperidine in DMF (2 × 20 min) the Fmoc-protected 
amino acids (4 equiv, 0.152 mmol) were coupled using PyBOP and HOBt (4 equiv each, 
0.152 mmol) as the coupling reagents and DIEA (10 equiv, 0.38 mmol) as the base in 
DCM:DMF (1:1, 3–4 mL) for 2 h (unless otherwise noted) on a manual multiple peptide 
synthesis apparatus (CHOIR)22 to afford the linear fragments. The side chains of Lys and 
Arg were protected by Boc and Pbf, respectively; those of Dap, Dab and Orn were protected 
by Mtt, and those of D-Asp and L-Asp were protected by Pip.
The (5–11) linear precursors of the cyclic peptides were synthesized by these standard 
procedures. Selective deprotection of the Pip and Mtt protecting groups on D-Asp and Dap, 
respectively, was performed using 3% TFA and 5% TIS in DCM (3 × 10–15 min). The 
cyclizations were performed using PyClocK and HOAt (4 equiv each) with DIEA (10 equiv) 
as the base in DCM:DMF (1:1) (4 mL for 200 mg peptide-resin) for 24 h, with the coupling 
reagents refreshed after every 8–12 h unless otherwise noted. The cyclizations were 
monitored using the qualitative ninhydrin test.23 Any remaining unreacted free amine of 
Dap was capped by treatment with acetyl imidazole (16 equiv, 0.61 mmol) with DIEA (8 
equiv) as the base in DMF(∼ 3 mL) for 30 min. Further extension of the peptide assembly 
up to Gly2 afforded the cyclic (2-11) peptide fragments.
Coupling of the N-terminal amino acid to the (2-11) peptide: Prior to coupling, complete 
dissolution of the N-alkyl-Tyr-OH (2 equiv) was achieved by heating to 80–120 °C in DMF 
(1 mL/0.02 mmol of N-alkyl amino acid), followed by cooling to rt (unless otherwise 
indicated) and subsequent addition of PyClock and HOAt (2 equiv each) plus DIEA (6 
equiv). The coupling reactions were generally complete after 12 h, as indicated by the 
qualitative ninhydrin test.
Final deprotection of the peptides: The peptides were cleaved from the resin using 
Reagent B30 (87.5% TFA, 5% water, 5% phenol and 2.5% TIS, 4–5 mL/200 mg resin). The 
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solutions were filtered, diluted with 10% aqueous acetic acid (10–15 mL), and extracted 
with diethyl ether (3 × 10 mL). The ether extracts were back extracted with 10% acetic acid 
(10 mL); the combined aqueous solutions were pooled and lyophilized to give the crude 
peptides.
Synthesis of linear peptides 2 and 3: The linear (2-11) fragments were synthesized as 
described above under the general procedure except that Fmoc-DAsn(Trt)OH and Fmoc-
Dap(Mtt)OH were used in a 2-fold excess for the synthesis of peptides 2 and 3, respectively. 
In addition, for peptide 3 the coupling of Fmoc-Dap(Mtt)-OH to the peptide resin was 
performed using PyClocK and HOAt (2 equiv each) in the presence of DIEA (6 equiv) in 
DCM:DMF (1:1, 4 mL). For peptide 3, the Mtt on Dap was selectively deprotected by 3% 
TFA and 5% TIPS in DCM (3 × 10 min, 3–4 mL each time), followed by acetylating with 
acetyl imidazole (16 equiv, 0.61 mmol) in the presence of DIEA (8 equiv) in DMF (3 mL) 
for 1 h. The coupling of N-benzyl-Tyr-OH (2 equiv) to the (2-11) fragment was performed 
according to the general procedure described above.
Synthesis of [N-benzyl-D-Tyr1]zyklophin and peptides 4–9 and 14: The (2-11) cyclic 
peptide fragment was synthesized according to the general procedure described above. For 
the D-Tyr derivative of zyklophin N-benzyl-D-Tyr (5.16 mg, 0.019 mmol, 2 equiv) was 
dissolved in DMF (2 mL) by heating to 85 °C, the solution cooled to room temperature 
followed by addition of PyClocK, HOAt (2 equiv each) and DIEA (6 equiv), and coupled to 
the (2-11) peptide for 12 h. In the case of peptide 5 N-allyl-Tyr-OH (20 mg, 0.076 mmol, 2 
equiv) was dissolved in DMF (6 mL) by heating to 105 °C. Since the solution became turbid 
when it was cooled to ∼70 °C, the coupling reagents were added to the amino acid solution 
at 105 °C. The solution was then cooled to rt, DIEA (6 equiv) added and the activated amino 
acid reacted with the (2-11) peptide fragment for 12 h to obtain peptide 5. For peptide 7 
complete dissolution of N-phenethyl-Tyr-OH (33 mg, 0.114 mmol, 2 equiv) was achieved 
by heating to 115 °C in DMF (10 mL). The solution was cooled to ∼70 °C, followed by the 
addition to PyClocK and HOAt (2 equiv. each). Subsequently, the solution was cooled to rt 
followed by the addition of DIEA (6 equiv). The amino acid was reacted with the (2-11) 
peptide fragment for 24 h with reagents replaced after 12 h. In the synthesis of peptide 9, N-
benzyl-Ala (2 equiv.) was heated to 85 °C in DMF (3.5 mL), followed by cooling the 
solution to 60 °C before adding PyClocK and HOAt (2 equiv each) and DIEA (6 equiv). The 
coupling reaction was performed for 24 h with the amino acid and coupling reagents 
replaced after 12 h.
For peptide 4 Fmoc-NMe-Tyr(OtBu)-OH (54 mg, 0.114 mmol, 2 equiv) was dissolved in 
DMF (5 mL) at room temperature and coupled to the (2-11) cyclic peptide using PyBOP (60 
mg, 0.114 mmol, 2 equiv) and HOBt (16 mg, 0.114 mmol, 2 equiv) in the presence of DIEA 
(6 equiv), followed by subsequent removal of the Fmoc group to afford peptide 4. For 
peptide 8 Fmoc-Tyr(tBu)-OH (52 mg, 0.114 mmol, 4 equiv) was coupled to the (2-11) 
peptide fragment in the presence of PyBOP (60 mg, 0.114 mmol, 4 equiv), HOBt (15 mg, 
0.114 mmol, 4 equiv each) and DIEA (10 equiv) in DCM:DMF (1:1, 3 mL) for 2 h. 
Following Fmoc deprotection of Tyr, the N-terminus of the Tyr was reacted with benzoic 
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anhydride (0.025 mg, 0.114 mmol, 4 equiv) and DIEA (8 equiv) in DMF (2–3 mL) 
overnight.
For peptide 6 Alloc-N-CPM-Tyr(Alloc)-OH (23 mg, 0.057 mmol, 2 equiv) was dissolved in 
DMF (3 mL) at room temperature, and the coupling to the (2-11) peptide performed with 
PyClocK (31 mg, 0.057 mmol, 2 equiv) and HOAt (8 mg, 0.057 mmol, 2 equiv) in the 
presence of DIEA (6 equiv) for 1 h, followed by the subsequent removal of the Alloc group 
(see below) to afford protected peptide 6 on the resin. For peptide 14 Alloc-N-benzyl-Phe-
OH (20 mg, 0.057 mmol, 2 equiv) was dissolved in DMF (3 mL) at rt with PyClocK and 
HOAt (2 equiv each) and DIEA (6 equiv) and coupled to the (2-11) peptide-resin. The 
coupling reaction was performed for 1 h, followed by subsequent removal of the Alloc 
group (see below) to afford the protected peptide 14 on resin.
Alloc deprotection of peptides 6 and 14: The resin was swollen in DCM (2 × 5 min), 
phenylsilane (24 equiv/ g of resin) was added, and the mixture was bubbled with N2 for 5 
min. Tetrakis-(triphenylphosphine) palladium (0.3 equiv) was added, and a septum with a 
needle was fixed onto the reaction vessel to allow the evolved carbon dioxide to escape. 
After shaking for 12 h the solution was drained, and the resin subjected to a series of washes 
as follows: DCM (4 × 1 min), THF (4 × 1 min), DCM (3 × 1 min), DMF (3 × 1 min), 0.5 % 
DIEA in DMF (3 × 2 min), 0.2 M sodium diethyldithiocarbamate in DMF (3 × 15 min), 
DMF (3 × 2 min), DCM (3 × 1 min), and methanol (3 × 1 min), followed by drying of the 
resin.24, 31
Synthesis of cyclic peptides 10–13: The synthesis of peptide 10 was performed according 
to the general procedure described above with Ala incorporated in position 4. For peptides 
11–13 the (5–11) linear peptide fragments with Ala incorporated in the indicated position 
were synthesized as described under the general procedure. Following selective deprotection 
by 3% TFA and 5% TIPS (3 × 10 min) in DCM, the cyclization reactions were performed 
for 24 h using PyClocK and HOAt (4 equiv each) in the presence of DIEA (6 equiv) in 
DCM:DMF (1:1, 4 mL) with the reagents replaced after 12 h. Following capping with acetyl 
imidazole the peptides were extended up through Gly2 as described under the general 
procedure. The coupling of N-benzyl-Tyr-OH to the (2-11) fragments followed the general 
procedure as described above to obtain peptides 11-13.
Synthesis of cyclic peptides 15-17: For peptide 15 [D-Asp(OPip)5,Dab(Mtt)8]Dyn A-
(5-11)-NH2 was synthesized on resin according to the general procedure described above, 
except that Fmoc-Dab(Mtt)OH (2 equiv) was coupling three times for 2 h each during the 
initial two couplings and overnight for the third coupling. Subsequently, the Pip and Mtt 
protecting groups on D-Asp and Dab, respectively, were selectively deprotected, and the 
peptide was cyclized for 36 h as described above, with coupling agents replaced every 8 h. 
Any unreacted free amine of Dab was acetylated as described above for Dap. Further 
extension of the peptide chain up through Gly2 was performed as described above under the 
general procedure. For peptides 16 and 17 the (5-11) linear peptide fragments were 
synthesized by the general procedure as described above. The Pip and Mtt protecting groups 
on D-Asp and Orn, respectively (peptide 16) and L-Asp and Dap, respectively (peptide 17) 
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were selectively deprotected using 3% TFA and 5% TIS in DCM (3 × 10 min). The peptides 
were cyclized for 36 h using PyClocK and HOAt (4 equiv each) in the presence of DIEA (6 
equiv.) in DCM:DMF (1:1, 4 mL) with the reagents replaced every 12 h. Following capping 
with acetyl imidazole the peptide was extended up through Gly2 as described under the 
general procedure. Subsequent coupling of N-benzyl-Tyr-OH to the corresponding (2-11) 
fragments was done as described for the general procedure to afford peptides 15–17.
Purification and analysis of the peptides: The crude peptides were purified by preparative 
reversed phased HPLC on a Vydac C18 column (10 µ, 300 Å, 22 × 250 mm) equipped with 
a Vydac C18 guard cartridge using an LC-AD Shimadzu liquid chromatograph system 
equipped with an SPD-10A VP system controller and SPD-10A VP UV-Vis detector. For 
purification, a linear gradient of 5–40% aqueous acetonitrile containing 0.1% TFA over 35 
min, at a flow rate of 18 mL/min, was used. The purifications were monitored at 214 nm. 
The purity of the final peptides was verified on a Vydac 218-TP column (5 µ, 300 Å, 4.6 
mm x 50 mm) equipped with a Vydac guard cartridge on a Shimadzu LC-10AT VP 
analytical HPLC liquid chromatograph (equipped with SCL-10A VP system controller and 
SPD-10A VP UV-Vis detector) or on an Agilent 1200 series liquid chromatograph system 
equipped with a multiple wavelength UV-Vis detector. Three systems were used for the 
analyses: 1) a linear gradient of 5–50% solvent B (solvent A = aqueous 0.1% TFA and 
solvent B = acetonitrile containing 0.1% TFA) over 45 min at a flow rate of 1 mL/min 
(system 1), 2) a linear gradient of 15–60% solvent B (solvent A = aqueous 0.1% TFA and 
solvent B = methanol containing 0.1% TFA) over 45 min at a flow rate of 1.0 mL/min 
(system 2), and 3) a linear gradient of 1–21% solvent B (solvent A = aqueous 0.09 M TEAP, 
pH = 2.5 and solvent B = acetonitrile) over 40 min. The final purity of all peptides by both 
analytical systems was ≥ 98% (see Table 2). Molecular weights of the compounds were 
determined by ESI-MS using a time of flight mass spectrometer analyzer (LCT premier, 
Waters, Milford, MA).
Pharmacological evaluation
Radioligand binding assays—Radioligand binding assays were performed as 
previously described17 using cloned rat KOR and MOR and mouse DOR stably expressed 
on CHO cells. Incubations with isolated membrane protein were performed in triplicate with 
concentrations of the cyclic tetrapeptides from 0.1 nM to 10 µM for 90 min in 50 mM Tris, 
pH 7.4 at 22 °C using [3H]diprenorphine (Kd = 0.45 nM), [3H]DAMGO ([D-
Ala2,NMePhe4,glyol]enkephalin, Kd = 0.49 nM), and [3H]DPDPE (cyclo[D-Pen2,D-
Pen5]enkephalin, Kd = 1.76 nM) as radioligands in assays for KOR, MOR, and DOR, 
respectively (Bmax = 2.27, 2.20, and 1.45 pmol/mg protein, respectively). Non-specific 
binding was determined in the presence of 10 µM unlabeled Dyn A(1-13)NH2, DAMGO 
and DPDPE for KOR, MOR, and DOR, respectively. Reported Ki values for the analogs are 
the means ± S.E.M. from at least three independent experiments except where noted.
Agonist stimulated GTPγS assay—The binding of the GTP analog [35S]GTPγS (0.1–
0.2 nM) to membranes containing KOR was performed in duplicate for 90 min in 50 mM 
HEPES, pH 7.4, at 22 °C as described previously.32 Specific binding was defined as total 
binding minus nonspecific binding that occurring in the presence of 3 µM unlabeled GTPγS. 
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At least two independent experiments were performed to evaluate the agonist activity of the 
analogs at 10 µM compared to the full agonist Dyn A(1-13)NH2; KB values from the Schild 
analysis are the mean ± S.E.M. from at least three independent experiments except where 
noted.
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Structures of Dyn A(1-11)NH2 and zyklophin (1)
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Separation of a diastereomeric mixture containing [N-benzyl-D-Tyr1]zyklophin and 
zyklophin using a) a linear gradient of aqueous acetonitrile containing 0.1% TFA (solvent A 
= aqueous 0.1% TFA and solvent B = acetonitrile containing 0.1% TFA, 10–25% solvent B 
over 30 min) and b) a linear gradient of TEAP (solvent A = aqueous 0.09 M TEAP, pH 2.5, 
and solvent B = acetonitrile, 1–21% solvent B over 40 min). tR for the D-Tyr diastereomer 
of zyklophin = 17.3 min and for zyklophin = 18.2 min. c) Zyklophin (tR = 18.3 min) 
synthesized by the standard procedure and analyzed using the TEAP solvent system showed 
no detectable epimerization.
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Chromatograms of peptide 14 synthesized by a) the standard procedure and b) using Alloc-
N-benzyl-Phe using the TEAP solvent system.
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Schild regression analysis of the ability of zyklophin (1) and peptides 6, 7 and 14 to produce 
rightward shifts in the Dyn A(1-13)-NH2 concentration-response relationships for 
stimulation of [35S]GTPγS binding. Data depicted were pooled from 2–5 experiments for 
each peptide. The 95% confidence intervals for the KB values are listed in Table 4.
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Synthesis of amino acid derivatives
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Solid phase synthesis of cyclic peptides 4, 5, 7–9 and 15–17
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Table 1
Analogs of zyklophin; changes from zyklophin are shown in bold.
A) Linear analogs
  2 NBn-Tyr1-Gly-Gly-Phe-DAsn5-Arg-Arg-Ile-Arg-Pro-Lys-NH2
  3 NBn-Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-Dap(Ac)8-Arg-Pro-Lys-NH2
B) Cyclic analogs
R X5 Y8 Other substitutions
  1 (Zyklophin) Bn D-Asp Dap
N-terminal modifications
  4 Me D-Asp Dap
  5 CH2=CH-CH2 D-Asp Dap
  6 CPM D-Asp Dap
  7 Phenethyl D-Asp Dap
  8 Bz D-Asp Dap
Amino acid
substitutions
  9 Bn D-Asp Dap Ala1
  10 Bn D-Asp Dap Ala4
  11 Bn D-Asp Dap Ala6
  12 Bn D-Asp Dap Ala7
  13 Bn D-Asp Dap Ala9
  14 Bn D-Asp Dap Phe1
Ring variants
  15 Bn D-Asp Dab
  16 Bn D-Asp Orn
  17 Bn L-Asp Dap
Bn = benzyl
Bz = benzoyl
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Table 2
Analytical data for the peptides








2 15.4 (>99.5) 18.0 (>99.5) [M + 3H]3+ = 484.9 [M + 3H]3+ = 484.9
[M + 2H]2+ = 726.9 [M + 2H]2+ = 726.9
3 17.7 (99.4) 23.1 (>99.5) [M + 3H]3+ = 489.6 [M + 3H]3+ = 489.6
[M + 2H]2+ = 733.9 [M + 2H]2+ = 733.9
4 11.3 (>99.5) 13.1 (99.4) [M + 3H]3+ = 444.9 [M + 3H]3+ = 444.9
[M + 2H]2+ = 666.8 [M + 2H]2+ = 666.9
5 12.1 (>99.5) 14.2 (>99.5) 11.9 (>99.5) [M + 3H]3+ = 453.5 [M + 3H]3+ = 453.6
[M + 2H]2+ = 679.8 [M + 2H]2+ = 679.9
6 13.1 (>99.5) 14.4 (99) 13.5 (>99.5) [M + 3H]3+ = 458.2 [M + 3H]3+ = 458.2
[M + 2H]2+ = 686.8 [M + 2H]2+ = 686.8
7 17.0 (>99.5) 15.3 (>99.5) 21.52 (98.9) [M + 3H]3+ = 474.9 [M + 3H]3+ = 474.9
8 18.1 (>99.5) 23.3 (>99.5) [M + 3H]3+ = 474.9 [M + 3H]3+ = 474.9
[M + 2H]2+ = 711.8 [M + 2H]2+ = 711.9
9 13.3 (>99.5) 13.3 (>99.5) 11.58 (>99.5) [M + 3H]3+ = 439.5 [M + 3H]3+ = 439.6
10 10.1 (>99.5) 8.0 (>99.5) [M + 3H]3+ = 444.9 [M + 3H]3+ = 444.9
[M + 2H]2+ = 666.8 [M + 2H]2+ = 666.9
11 15.1 (>99.5) 18.5 (>99.5) [M + 3H]3+ = 441.9 [M + 3H]3+ = 441.9
[M + 2H]2+ = 662.3 [M + 2H]2+ = 662.4
12 14.8 (99.0) 15.2 (98.9) [M + 3H]3+ = 441.9 [M + 3H]3+ = 441.9
[M + 2H]2+ = 662.3 [M + 2H]2+ = 662.4
13 14.8 (>99.5) 14.6 (>99.5) [M + 3H]3+ = 441.9 [M + 3H]3+ = 441.9
[M + 2H]2+ = 662.3 [M + 2H]2+ = 662.3
14 17.0 (98.1) 15.6 (>99.5) 20.1 (98.7) [M + 3H]3+ = 464.9 [M + 3H]3+ = 464.9
15 15.3 (>99.5) 18.5 (>99.5) [M + 3H]3+ = 474.9 [M + 3H]3+ = 474.9
[M + 2H]2+ = 711.9 [M + 2H]2+ = 711.9
16 15.1 (>99.5) 18.1 (>99.5) [M + 3H]3+ = 479.6 [M + 3H]3+ = 479.6
[M + 2H]2+ = 718.9 [M + 2H]2+ = 718.9
17 13.2 (99.1) 15.2 (99.0) [M + 3H]3+ = 470.2 [M + 3H]3+ = 470.2
[M + 2H]2+ = 704.8 [M + 2H]2+ = 704.8
a
Aqueous acetonitrile containing 0.1% TFA, λ = 214 nm;
b
aqueous methanol containing 0.1% TFA λ = 220 nm;
c
aqueous acetonitrile containing 0.09 M TEAP, λ = 214 nm. See the experimental section for details.
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Table 3









2, D-Asn5 412 ± 60 0.23 2440 ± 570 6
3, Dap(Ac)8 28.6 ± 0.6 3.3 157 ± 25 5
4,N-Me 160 ± 18 0.60 1490 ± 410 9
5,N-Allyl 326 ± 72 0.29 11000 ± 4,000 34
6,N-CPM 44.4 ± 16.3 2.1 10900 ± 2700 245
7,N-Phenethyl 62.0 ± 19.9 1.5 8470 ± 560 137
8,N-Benzoyl 346 ± 21 0.28 10600 ± 1700 31
9, Ala1 516 ± 82 0.18 >10000 >19
10, Ala4 4010 ± 360 0.02 > 10,000 (2) >2.5
11, Ala6 1750 ± 540 0.05 11500 ± 2600 7
12, Ala7 293 ±118 0.32 >10000 >34
13, Ala9 168 ± 50 0.57 2550 ± 640 15
14, Phe1 68.7 ±18.1 1.4 11300 ± 1980 164
15, Dab8 403 ± 91 0.24 3200 ± 850 8
16, Orn8 222 ± 5 0.42 8260 ± 1870 37
17, L-Asp5 410 ± 17 0.23 2610 ± 780 6
1, (zyklophin) 95.2 ± 28.8e 1.0 4380 ± 560 46
a
Ki values for KOR and MOR were obtained from n ≥ 3 independent experiments except where noted.
b




The analogs exhibited minimal DOR affinity (<20% inhibition of binding when screened against DOR at 10 µM, Ki > 5 µM) except for 3 (Ki = 
2290 ± 520 nM).
e
95% confidence interval 30–160 nM (n = 10).
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Table 4
KOR antagonist potencies of selected zyklophin analogs in the Dyn A(1-13)NH2 stimulated GTPγS assay
Peptide KB (95% Confidence
interval), nMa,b
6 [N-CPM] 12.1 (0.8–61)
7 [N-Phenethyl] 92.5 (9.0–6110)
14 [Phe1] 29.7 (0.5–1320)
1 (zyklophin) 336 (180–535)
a
KB values derived from Schild analysis in the GTPγS assay. Values for the peptides are the average from 2–5 independent experiments. For 
reference the norBNI KB = 0.074 nM
b
Peptide 12 did not cause a significant shift in the Dyn A(1-13)NH2 concentration-response curve at concentrations up to 10 µM.
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